Applied Clinical Trials Online2h
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...
Applied Clinical Trials Online23h
API-CAT Trial Shows Reduced-Dose Eliquis Matches Full Dose in Preventing Venous Thromboembolism, Lowers Bleeding Risk in Cancer Patients
The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...